Amin Radparvar, MD
Endocrinology, Diabetes & Metabolism · St Peters, MONPI 1316987837
Payments from drug & device makers
Across 155 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$376
- Lilly USA, LLC$338
- Novo Nordisk$315
- Medtronic$302
- Abbott$260
- AstraZeneca$246
- plus $988 from 15 others
What the payments were for
- Food & beverage$2,70696%
- Gifts$1194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 18 | $376 |
| Lilly USA, LLC | 19 | $338 |
| Novo Nordisk | 17 | $315 |
| Medtronic(2 entities) | 12 | $302 |
| Abbott | 22 | $260 |
| AstraZeneca | 13 | $246 |
| Boehringer Ingelheim | 10 | $169 |
| Amarin Pharma, Inc. | 9 | $134 |
| BETA Bionics, Inc. | 6 | $99 |
| Bayer | 4 | $83 |
| AbbVie | 3 | $72 |
| Dexcom, Inc. | 3 | $70 |
| Insulet Corporation | 4 | $61 |
| Intuity Medical Inc | 3 | $61 |
| Amgen | 3 | $57 |
| Sequel Med Tech, LLC | 2 | $56 |
| Pfizer | 3 | $48 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Lifescan, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,825 in reported general payments places this provider in the 55th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 203 | $331,164 |
| JardianceEmpagliflozin | 287 | $309,500 |
| MounjaroTirzepatide | 193 | $292,592 |
| FarxigaDapagliflozin Propanediol | 255 | $267,137 |
| Tresiba Flextouch U-100Insulin Degludec | 119 | $95,151 |
| RybelsusSemaglutide | 40 | $75,899 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $74,932 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 42 | $49,161 |
| JanuviaSitagliptin Phosphate | 40 | $40,699 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $33,969 |
| TradjentaLinagliptin | 40 | $30,147 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $27,306 |
| Humalog Kwikpen U-100Insulin Lispro | 72 | $23,959 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $21,574 |
| FiaspInsulin Aspart (Niacinamide) | 19 | $21,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $315 | $441,697290 claims |
| Boehringer IngelheimJardiance, Tradjenta | $169 | $339,647327 claims |
| Lilly USA, LLCMounjaro, Humalog, Humulin N, Insulin Lispro | $338 | $305,395276 claims |
| AstraZenecaFarxiga | $246 | $267,137255 claims |
| PfizerEliquis | $48 | $15,75915 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $7,198723 claims |
| AbbVieSynthroid | $72 | $5,14471 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in St Peters
- Ralph DudaSpringfield$3M
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Christopher CaseJefferson City$692K
- Gregory LedgerSpringfield$690K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Julie SilversteinSaint Louis$536K
- Ralph OiknineChesterfield$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.